Evaluating effect of intravenous midazolam on duration of spinal anesthesia

Clinical trial of evaluating effect of intravenous midazolam on duration of spinal anesthesia in comparison to control group

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014090716415N5

Enrollment

Registered

2014-09-29

Start date

2014-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Anesthesia. Spinal anesthetics causing adverse effects in therapeutic use

Interventions

Intervention 1: Intravenous Midazolam injection. Intervention 2: Intravenous normal saline (placebo).

Treatment - Drugs

Placebo

Intravenous Midazolam injection

Intravenous normal saline (placebo)

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: 20 to 60 years old; class American Society of Anesthesiologists (ASA) I or II; no contraindication for midazolam; no benzodiazepine medication before surgery; no history of alcohol or other substance abuse

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Duration of sensory and motor block. Timepoint: Every 2-5 minutes. Method of measurement: Pinprick testing.	—

Secondary

Measure	Time frame
Sedation Score. Timepoint: Every 5 minutes. Method of measurement: Ramsy Sedation Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGolparvar M MD

Isfahan University of Medical Sciences

golparvar@med.mui.ac.ir+98 31 3624 9031

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026